Takeda Pharmaceutical Co (4502) Stock Forecast & Price Target

Compare

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4502 Analyst Ratings

Moderate Buy

1 Buy

1 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Takeda

Pharmaceutical Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4502 Stock 12 Month Forecast

Average Price Target

¥5,350.00

▲(26.72% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Takeda Pharmaceutical Co in the last 3 months. The average price target is ¥5,350.00 with a high forecast of ¥6,200.00 and a low forecast of ¥4,500.00. The average price target represents a 26.72% change from the last price of ¥4,222.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3998":"¥3,998","6201":"¥6,201","4548.75":"¥4,548.8","5099.5":"¥5,099.5","5650.25":"¥5,650.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥6K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.35K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥4.50K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3998,4548.75,5099.5,5650.25,6201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4835,4940,5045,5150,5255,5360,5465,5570,5675,5780,5885,5990,6095,{"y":6200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4835,4874.615384615385,4914.2307692307695,4953.846153846154,4993.461538461538,5033.076923076923,5072.692307692308,5112.307692307692,5151.923076923077,5191.538461538462,5231.153846153846,5270.7692307692305,5310.384615384615,{"y":5350,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4835,4809.2307692307695,4783.461538461538,4757.692307692308,4731.923076923077,4706.153846153846,4680.384615384615,4654.615384615385,4628.846153846154,4603.076923076923,4577.307692307692,4551.538461538462,4525.7692307692305,{"y":4500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3999.076,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4025.857,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4145.419,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4407.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4273.487,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4179.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4294.991,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4121.979,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4368.301,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4260,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4153,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4509,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4835,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥6,200

Average Price Target¥5,350

Lowest Price Target¥4,500

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Shinichiro Muraoka

Morgan Stanley

¥6,200

Buy

46.85%

Upside

Initiated

01/13/26

Takeda resumed with an Overweight at Morgan StanleyTakeda resumed with an Overweight at Morgan Stanley

Miki Sogi

Bernstein

¥4,500

Hold

6.58%

Upside

Assigned

10/23/25

Bernstein Reaffirms Their Hold Rating on Takeda Pharmaceutical Co (TKPHF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

¥5,200→¥5,000

Buy

18.43%

Upside

Reiterated

10/14/25

Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)

Koichi Mamegano

Bank of America Securities

¥5,500

Buy

30.27%

Upside

Reiterated

09/08/25

Promising Phase 3 Results for Takeda's Oveporexton Boost Buy Rating

Hiroyuki Matsubara

Nomura

¥5,400→¥5,300

Buy

25.53%

Upside

Reiterated

06/12/25

Nomura Keeps Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)

Michael Nedelcovych

TD Cowen

¥5,135

Buy

21.62%

Upside

Reiterated

05/21/25

Unknown Analyst

Bloomberg Ind.

Not Ranked

Bloomberg Ind.

¥5,500→¥5,100

Buy

20.80%

Upside

Reiterated

05/08/25

Kelly Shi

Jefferies

¥5,500→¥5,100

Buy

20.80%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Co (Other OTC: TKPHF), Opus Genetics (NASDAQ: IRD) and CareCloud (NASDAQ: CCLD)

Seiji Wakao

J.P. Morgan

¥4,300→¥4,500

Hold

6.58%

Upside

Reiterated

03/27/25

Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY4,500 at JPMorganJPMorgan analyst Seiji Wakao raised the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY4,500.00 (from JPY4,300.00) while maintaining a Neutral rating.

Zhijie Zhao

CLSA

¥5,800

Buy

37.38%

Upside

Initiated

03/13/25

CLSA Starts Takeda Pharmaceutical (4502:JP) (TAK) at Outperform (2)CLSA analyst Zhijie Zhao initiates coverage on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) with a Outperform (2) rating and a price target of JPY5,800.00.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Shinichiro Muraoka

Morgan Stanley

¥6,200

Buy

46.85%

Upside

Initiated

01/13/26

Takeda resumed with an Overweight at Morgan StanleyTakeda resumed with an Overweight at Morgan Stanley

Miki Sogi

Bernstein

¥4,500

Hold

6.58%

Upside

Assigned

10/23/25

Bernstein Reaffirms Their Hold Rating on Takeda Pharmaceutical Co (TKPHF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

¥5,200→¥5,000

Buy

18.43%

Upside

Reiterated

10/14/25

Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)

Koichi Mamegano

Bank of America Securities

¥5,500

Buy

30.27%

Upside

Reiterated

09/08/25

Promising Phase 3 Results for Takeda's Oveporexton Boost Buy Rating

Hiroyuki Matsubara

Nomura

¥5,400→¥5,300

Buy

25.53%

Upside

Reiterated

06/12/25

Nomura Keeps Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)

Michael Nedelcovych

TD Cowen

¥5,135

Buy

21.62%

Upside

Reiterated

05/21/25

Unknown Analyst

Bloomberg Ind.

Not Ranked

Bloomberg Ind.

¥5,500→¥5,100

Buy

20.80%

Upside

Reiterated

05/08/25

Kelly Shi

Jefferies

¥5,500→¥5,100

Buy

20.80%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Co (Other OTC: TKPHF), Opus Genetics (NASDAQ: IRD) and CareCloud (NASDAQ: CCLD)

Seiji Wakao

J.P. Morgan

¥4,300→¥4,500

Hold

6.58%

Upside

Reiterated

03/27/25

Zhijie Zhao

CLSA

¥5,800

Buy

37.38%

Upside

Initiated

03/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Takeda Pharmaceutical Co

3 Months

xxx

Success Rate

2/3 ratings generated profit

Average Return

+3.13%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.13% per trade.

1 Year

Koichi MameganoBank of America Securities

Success Rate

7/7 ratings generated profit

Average Return

+16.84%

reiterated a buy rating 4 months ago

Copying Koichi Mamegano's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +16.84% per trade.

2 Years

xxx

Success Rate

3/3 ratings generated profit

Average Return

+9.27%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +9.27% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4502 Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4502 has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 4502 average Analyst price target in the past 3 months is 5,350.00.

Each month's total comprises the sum of three months' worth of ratings.

4502 Financial Forecast

4502 Earnings Forecast

Next quarter’s earnings estimate for 4502 is ¥52.18 with a range of ¥52.18 to ¥52.18. The previous quarter’s EPS was -¥7.83. 4502 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 4502 has Performed in-line its overall industry.

4502 Sales Forecast

Next quarter’s sales forecast for 4502 is ¥1.20T with a range of ¥1.13T to ¥1.26T. The previous quarter’s sales results were ¥1.11T. 4502 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 4502 has Performed in-line its overall industry.

4502 Stock Forecast FAQ

What is JP:4502’s average 12-month price target, according to analysts?

Based on analyst ratings, Takeda Pharmaceutical Co’s 12-month average price target is 5,350.00.

What is JP:4502’s upside potential, based on the analysts’ average price target?

Takeda Pharmaceutical Co has 26.72% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Takeda Pharmaceutical Co a Buy, Sell or Hold?

Takeda Pharmaceutical Co has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.

What is Takeda Pharmaceutical Co’s share price target?

The average share price target for Takeda Pharmaceutical Co is 5,350.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥6,200.00 ,and the lowest forecast is ¥4,500.00. The average share price target represents 26.72% Increase from the current price of ¥4,222.

What do analysts say about Takeda Pharmaceutical Co?

Takeda Pharmaceutical Co’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Takeda Pharmaceutical Co?

To buy shares of JP:4502, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Takeda Pharmaceutical Co (4502) Stock Forecast & Price Target

4502 Analyst Ratings

4502 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Takeda Pharmaceutical Co

4502 Analyst Recommendation Trends

4502 Financial Forecast

4502 Earnings Forecast

4502 Sales Forecast

4502 Stock Forecast FAQ

Detailed List of Analyst Forecasts